US Breast There is no relevant literature to support the use of US for breast cancer screening in this clinical setting. Variant 3: Breast cancer screening. Transfeminine (male-to-female) patient with no hormone use (or hormone use less than 5 years) at any age. Average-risk patient. Recommendations for breast cancer screening in transfeminine patients are typically based on the male sex assigned at birth, the number of years of feminizing hormone exposure, breast development, and any significant risk factors for breast cancer. Digital Breast Tomosynthesis Screening There is no relevant literature to support the use of DBT for breast cancer screening in this clinical setting. In the absence of identifiable risk factors for breast cancer, general screening has no role because of an overall low prevalence of disease. The lifetime risk of breast cancer in transfeminine patients with no hormone use and no significant risk factors is considered to be equivalent to the average risk in cisgender men, which is 0.1% (compared with 12.4% in the average-risk cisgender female) [1,26]. Mammography Screening There is no relevant literature to support the use of DBT for breast cancer screening in this clinical setting. In the absence of identifiable risk factors for breast cancer, general screening has no role because of an overall low prevalence of disease. The lifetime risk of breast cancer in transfeminine patients with no hormone use and no significant risk factors is considered to be equivalent to the average risk in cisgender men, which is 0.1% (compared with 12.4% in the average-risk cisgender female) [1,26]. MRI Breast Without and With IV Contrast There is no relevant literature to support the use of MRI breast without and with IV contrast to screen for breast cancer in this clinical setting. US Breast There is no relevant literature to support the use of US for breast cancer screening in this clinical setting.
Transgender Breast Cancer Screening. US Breast There is no relevant literature to support the use of US for breast cancer screening in this clinical setting. Variant 3: Breast cancer screening. Transfeminine (male-to-female) patient with no hormone use (or hormone use less than 5 years) at any age. Average-risk patient. Recommendations for breast cancer screening in transfeminine patients are typically based on the male sex assigned at birth, the number of years of feminizing hormone exposure, breast development, and any significant risk factors for breast cancer. Digital Breast Tomosynthesis Screening There is no relevant literature to support the use of DBT for breast cancer screening in this clinical setting. In the absence of identifiable risk factors for breast cancer, general screening has no role because of an overall low prevalence of disease. The lifetime risk of breast cancer in transfeminine patients with no hormone use and no significant risk factors is considered to be equivalent to the average risk in cisgender men, which is 0.1% (compared with 12.4% in the average-risk cisgender female) [1,26]. Mammography Screening There is no relevant literature to support the use of DBT for breast cancer screening in this clinical setting. In the absence of identifiable risk factors for breast cancer, general screening has no role because of an overall low prevalence of disease. The lifetime risk of breast cancer in transfeminine patients with no hormone use and no significant risk factors is considered to be equivalent to the average risk in cisgender men, which is 0.1% (compared with 12.4% in the average-risk cisgender female) [1,26]. MRI Breast Without and With IV Contrast There is no relevant literature to support the use of MRI breast without and with IV contrast to screen for breast cancer in this clinical setting. US Breast There is no relevant literature to support the use of US for breast cancer screening in this clinical setting.